Key facts
- This page summarizes Michael E. Prevoznik's Form 4 filing for QUEST DIAGNOSTICS INC (DGX).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2022, 15:50.
Michael E. Prevoznik - 07 Mar 2022 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)
- Reporting relationship
- SVP & General Counsel
- Issuer ticker
- DGX
- Reported as of
- 07 Mar 2022
- Net transaction value
- -$31,887
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2022, 15:50:50 UTC
- Prior SEC filing
- 02 Mar 2022
- Next SEC filing
- 19 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Michael E. Prevoznik
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael E. Prevoznik filed Form 4 for QUEST DIAGNOSTICS INC (DGX) on 09 Mar 2022.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: -$31,887.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DGX
transaction
Common Stock
Award
- Transaction value
- $1,501,759
- Shares
- +11,544
- Change %
- +29%
- Price
- $130.09
- Shares after
- 50,768
- Date
- 07 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
DGX
transaction
Common Stock
Tax liability
- Transaction value
- $691,558
- Shares
- -5,316
- Change %
- -10%
- Price
- $130.09
- Shares after
- 45,452
- Date
- 07 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
DGX
transaction
Common Stock
Sale
- Transaction value
- $842,088
- Shares
- -6,228
- Change %
- -14%
- Price
- $135.21
- Shares after
- 39,224
- Date
- 08 Mar 2022
- Ownership
- Direct
- Footnotes
- F3
DGX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,306
- Date
- 07 Mar 2022
- Ownership
- 401(k)/SDCP
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d).
Footnote F2
Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
Footnote F3
The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 31, 2020.
Footnote F4
These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.